相关实验视频
Updated: Jun 18, 2025

Ferric Chloride-induced Murine Thrombosis Models
Published on: September 5, 2016
XI因子抑制剂 - 抗血栓治疗中的新星?
1Department of Neurology with Experimental Neurology, Charité-Universitätsmedizin Berlin, Berlin, Germany; Center for Stroke Research Berlin (CSB), Berlin, Germany; Berlin Institute of Health (BiH), Berlin, Germany; German Center for cardiovascular Research (DZHK), Berlin, Germany.
新的XI因子抑制剂可有效预防血栓形成,降低出血风险. 单克隆抗体,小分子和反感寡核酸被用于各种疾病的研究,预计很快就会有结果.
科学领域:
- 血液静止和血栓形成
- 药理学 药理学是指药理学的学科.
- 药物开发 药物开发
背景情况:
- 血栓塞和血栓栓塞的预防需要高效的治疗方法,出血风险最小.
- 抑制XI因子是一个有希望的目标,有可能在没有显著出血的情况下降低血栓形成.
- 目前的研究重点是三个药物类别:单克隆抗体 (mAbs),小分子和反感性寡核酸 (ASOs).
研究的目的:
- 提供有关XI因子抑制剂药物开发现状的叙事概述.
- 总结正在进行的临床试验和不同的XI因子抑制剂类别的预期结果.
主要方法:
- 关于XI因子抑制剂的当前临床研究的审查.
- 药物类别的分析,包括单克隆抗体,小分子和反感性寡核酸.
- 专注于Abelacimab,Asundexian和Milvexian的第三阶段试验.
主要成果:
- 单克隆抗体 (mAbs) 试验的重点是手术后的DVT预防,目前正在进行心房的第三阶段研究.
- 像Asundexian和Milvexian这样的合成小分子正在进行非心性缺血性中风的第三阶段试验.
- 针对XI因子抑制的反感性寡核酸 (ASOs) 的临床试验处于早期阶段.
结论:
- XI因子抑制剂代表了对血栓形成和血栓栓塞的有前途的治疗策略.
- 需要从正在进行的第三期试验中获得进一步的临床数据,以确定疗效和安全性.
- 反意义寡核酸在早期发展阶段,需要进一步研究.
相关概念视频
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Clot Retraction and Fibrinolysis
Extrinsic and Intrinsic Pathways of Hemostasis
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
Therapeutic Index

